Comment on: Use of thrombopoietin receptor agonist (romiplostim) in neonatal autoimmune thrombocytopenia due to maternal immune thrombocytopenia

Pediatr Blood Cancer. 2019 Jun;66(6):e27706. doi: 10.1002/pbc.27706. Epub 2019 Mar 11.

Authors

Upendra Mahat¹, Ravi Talati¹, Eric Kodish¹

Affiliation

¹ Pediatric Hematology Oncology, Cleveland Clinic Children's, Cleveland, Ohio.

PMID: 30854752
DOI: 10.1002/pbc.27706

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Female
Humans
Infant, Newborn
Infant, Newborn, Diseases / drug therapy*
Infant, Newborn, Diseases / etiology
Maternal Exposure / adverse effects*
Prognosis
Purpura, Thrombocytopenic, Idiopathic / complications
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
Receptors, Fc / therapeutic use*
Receptors, Thrombopoietin / agonists*
Recombinant Fusion Proteins / therapeutic use*
Thrombopoietin / therapeutic use*

Substances

Receptors, Fc
Receptors, Thrombopoietin
Recombinant Fusion Proteins
Thrombopoietin
romiplostim